The Pharmaceutical Innovations Targeting Obesity

There is a waiting list for a weight-loss injection in practically every pharmacy in London, New York, or Copenhagen today. Ten years ago, this would have seemed unthinkable. Wegovy, Novo Nordisk’s popular semaglutide product, has been backordered for extended periods of time in several nations due to demand exceeding production capacity in a manner that nobody fully expected. In 2025 alone, Eli Lilly’s tirzepatide, marketed as Zepbound for obesity and Mounjaro for diabetes, brought in about $3.23 billion.

These aren’t specialty items for a tiny clinical clientele. For a condition that currently affects over 1.1 billion people worldwide—a 115 percent increase since 2010—they are becoming commonplace medications. Sensing the scope of what is possible, the pharmaceutical industry is expanding at a rate that even clinicians attempting to keep up with it find nearly bewildering.

The problem is that, in a significant sense, the drugs that have created the most excitement thus far are the first act. Semaglutide, liraglutide, and tirzepatide are GLP-1 receptor agonists that mimic the gut hormones that control insulin and appetite, prolonging feelings of fullness and delaying the emptying of the stomach.

They are effective. exceptionally effective in certain situations; trials have shown weight reductions of at least 15 to 20 percent. They don’t address the entire biological picture of obesity, and the pipeline that dozens of companies are currently assembling indicates that the field is aware of this. According to GlobalData’s 2025 statistics, there are currently over 600 obesity medication candidates in discovery or preclinical development worldwide. The majority of them aim to accomplish something that first-generation medications were unable to fully accomplish.

Retatrutide from Eli Lilly is arguably the most anticipated medication in development at the moment. Targeting GLP-1, GIP, and glucagon receptors concurrently, it is a triple agonist, and the preliminary findings are hard to overlook. After 48 weeks at the highest dose, phase II results demonstrated a reduction in body weight of up to 24.2 percent, which is greater than what current approved therapies accomplish in head-to-head comparisons.

Phase III results are anticipated in 2026, and there is a great deal of excitement in the investment and clinical communities. However, side effects are more noticeable at higher doses; these are primarily gastrointestinal, though one case of pancreatitis in the phase II trial raised concerns that scientists are closely monitoring. The field is publicly debating the tension between efficacy and tolerability, which are not always moving in the same direction.

The shift to oral formulations is another development that appears to be truly important. The majority of obesity drugs on the market today require subcutaneous injections, which are usually self-administered at home once a week using a pen. It is effective, but it has drawbacks, such as needle aversion, storage needs, and cost structures that mirror injectable manufacturing.

Positive phase III results for a 25 mg oral semaglutide pill have already been released by Novo Nordisk. In trials, Eli Lilly’s orforglipron, a once-daily tablet, produced statistically significant weight loss; however, its approximately 11 percent reduction at the highest tested dose is less than that of the injectable alternatives. An oral protein formulation is “really exciting” from a scientific perspective, according to Katrina Bicknell, a pharmacology professor at Reading School of Pharmacy. Practically speaking, tablets are easier to transport, store, and generally cost less over time, even though initial pricing usually takes some time to reflect that.

The biotech firms that are entering this market are bringing truly unique strategies. Survodutide, a dual glucagon and GLP-1 receptor agonist that demonstrated up to 19% weight loss in phase II trials, and petrelintide, which mimics the hormone amylin rather than GLP-1 entirely—two distinct biological levers working toward the same goal—are being developed by Zealand Pharma, a Danish company.

In phase II trials for its VK2735 candidate, California-based Viking Therapeutics reported weight loss of up to 14.7 percent after just 13 weeks, with 88 percent of participants losing at least 10 percent of body weight. Phase II results for the GLP-1 and GIP receptor agonist ribupatide from Massachusetts-based Kailera Therapeutics show a mean weight loss of up to 23.6 percent over 36 weeks. These figures are not incremental.

As this field develops, it seems like the discussion is moving from whether or not these drugs work to who can actually obtain them and how much they cost. Morgan Stanley projects that the global market for obesity medications will reach $150 billion by 2035; this estimate is based on anticipated demand rather than assured supply. Pricing is still a major concern, especially in health systems that are under pressure.

Industry observers are keeping an eye on the oral GLP-1 rollout in light of the 2019 launch of the first oral CGRP medications for migraine treatment, which maintained high prices despite lower manufacturing costs. The clinical advancement is truly remarkable. For the time being, access equity is still far less clear.

Beyond the well-known names, the preclinical pipeline is venturing into areas that seem very different from the first wave’s gut-hormone-targeting strategy. MGAT2 inhibitors, which alter the intestinal absorption of fat, are being developed by researchers. Bimagrumab and other anti-ActRII compounds target the muscle-fat balance, maintaining lean mass while decreasing adipose tissue.

This addresses a long-standing complaint that weight-loss medications can decrease total body mass without clearly differentiating between muscle and fat. The thermogenic effects of melanocortin receptor agonists through central nervous system pathways are being investigated. Finally, rather than focusing on just one hormonal lever, the biological complexity of obesity—which includes genetics, epigenetics, gut signaling, brain chemistry, and environmental factors—is being addressed from several perspectives simultaneously.

It’s difficult to ignore the fact that this development is happening faster than the surrounding social, clinical, and regulatory infrastructure. Even though retatrutide is still undergoing clinical trials, it has already sparked black market activity on social media, with people claiming to buy and sell it before it has received regulatory approval.

That is a cultural issue rather than a scientific one, and it illustrates how urgent the unmet need has become and how drastically the public’s perception of obesity treatment has changed in a matter of years. More quickly than the systems surrounding them can adjust, these drugs have transitioned from curiosity to urgency. The question that the field is now truly focused on answering is whether the next generation of medications can continue that progress more fairly, with improved tolerability and more transparent long-term data.